Embryo Glue® (エンブリオグルー)はヒアルロン酸入り胚移植用培養液です。 （グルー≒糊、接着剤）
Embryo Glue® はVitrolife社製、FDA（米国食品医薬品局）に認可されており、受精卵に対して安全で優秀かつ高価な培養液であることです。この培養液の使用より着床率、臨床妊娠率が高くなる可能性があると多く報告されている。
HCG500IU子宮内注入法EG （Embryo Glue）なしEGなしHCG500IU子宮内注入法
HCG500IU子宮内注入法EG （Embryo Glue）ありEGありHCG500IU子宮内注入法
Investigating the Optimal Time for Intrauterine Human
Chorionic Gonadotropin Infusion in Order to Improve IVF
Outcome: A Systematic Review and Meta-Analysis
Background/Aim: Studies on the impact of intrauterine human Chorionic Gonadotropin (hCG) administration in order to improve the In Vitro Fertilization (IVF) outcome have yielded conflicting results. The aim of the present systematic review and meta-analysis is to investigate whether timing of intrauterine hCG administration prior to embryo transfer affects its efficiency.
Materials and Methods:
A systematic search of the literature on Pubmed/Medline, Embase and Cochrane databases was performed. Only Randomized Control Trials were included in this metaanalysis.
Live birth rates were not improved
following hCG administration (RR=1.13, 95%CI=0.88-1.46, p=0.34) in the pooled results. Combined live birth and ongoing pregnancy rates were borderline statistically significant following hCG administration (RR=1.27, 95%CI=1.00-1.62, p=0.05). Following subgroup analysis regarding live birth and ongoing pregnancy rates, only the 5-12 minutes prior to the embryo transfer group reported a statistically significant improvement. Conclusion: Intrauterine infusion of hCG within an IVF-Intracytoplasmic Sperm Injection (ICSI) cycle improves outcome only when administered 5-12 min prior to embryo transfer.
Intrauterine injection of human chorionic gonadotropin
improves pregnancy outcome in patients with repeated
implantation failure in frozen-thawed embryo transfer
ABSTRACT Objective: To investigate whether intrauterine injection of human chorionic gonadotropin (hCG)
before the embryo transfer in a frozen-thawed transfer cycle can improve the pregnancy outcome in the patients with repeated implantation failure (RIF).
Methods: Prospective randomized-controlled trial was adopted. A total of 140 patients, who underwent thawed embryo transplantation and were in line with the diagnosis of RIF, were included. Other patients with some factors, such as uterine malformation, postoperative uterine
cavity sticking, tubal effusion, endocrine diseases and endometriosis, were excluded. The patients
were randomly divided into 2 groups through the computer random number table: an hCG
intrauterine perfusion group and a control group. There was no significant difference in the age,
the estradiol level, the number of transplanted embryos, the number of optimal embryos, and
the thickness of the endometrium before transplantation between the 2 group (all P>0.05). The hCG+G2 fluid and the G2 fluid were prepared on the day of embryo transfer, and 40 μL of which
was injected at an intrauterine site at 3 minutes before embryo transfer in the hCG intrauterine
perfusion group and the control group, respectively. The clinical pregnancy rate and implantation
rate in the 2 groups were compared.
Results: The implantation rate (28.99%(40/138) vs 17.99%(25/139) )and the clinical pregnancy rate (52.17%(36/69) vs 30.88%(21/68) ) in the hCG intrauterine perfusion group were higher than those in the control group (both P<0.05).
Conclusion: The intrauterine injection of hCG can improve the implantation rate and pregnancy
rate in cryopreserved embryo transfer in patients with RIF.
Effect of intrauterine injection of human chorionic gonadotropin before
frozen–thawed embryo transfer on pregnancy outcomes in women with endometriosis
Objective: To investigate the effect of human chorionic gonadotropin (hCG) intrauterine injection
before frozen–thawed embryo transfer (FET) in women with endometriosis.
Methods: This retrospective cohort study included 45 women with endometriosis who underwent
hCG intrauterine injection before FET; each woman was matched with three patients with
endometriosis who did not receive hCG intrauterine injection (controls). 0.04 mL of r-hCG intrauterine injection 1 day before FET. Data on pregnancy and
prenatal outcomes were extracted from medical records and compared.
Results: Patients in the hCG intrauterine injection group had significantly higher rates of pregnancy
and clinical pregnancy (64.4% and 57.8%, respectively) than controls (47.4% and 39.3%,
respectively). Neonatal birth weight for both singletons and twins was significantly higher
in the hCG group (3486458 g and 2710437 g, respectively) than in the control group
(3195±401 g and 2419±370 g, respectively).
Conclusion: Pregnancy rate, clinical pregnancy rate, and birth weight were improved in women
with endometriosis who underwent intrauterine hCG injection compared with those who did not receive hCG before FET.
Effect of intrauterine injection of human chorionic gonadotropin before fresh embryo transfer on IVF and ICSI outcomes: a meta‑analysis
Purpose This analysis was performed to evaluate the effects of intrauterine injection of human horionic gonadotropin (hCG) before fresh embryo transfer (ET) on the outcomes of in vitro ertilization and intracytoplasmic sperm injection.
Methods Randomized controlled trials (RCTs) were identified by searching electronic databases. The outcomes of live birth, clinical pregnancy, implantation, biochemical pregnancy, ongoing pregnancy, ectopic pregnancy, and miscarriage
between groups with and without hCG injections were analyzed. Summary measures were reported as risk ratios (RR) with 95% confidence intervals.
Results Six RCTs on fresh embryo transfer (ET) were included in the meta-analysis. A total of 2759 women undergoing fresh ET were enrolled (hCG group n = 1429; control group n = 1330). Intrauterine injection of hCG significantly increased
rates of biochemical pregnancy (RR 1.61) and ongoing pregnancy (RR 1.58) compared to controls. However, there were no significant differences in clinical pregnancy (RR 1.11), implantation (RR 1.17), miscarriage (RR 0.91), ectopic (RR 1.65) or live birth rates (RR 1.13) between the hCG group and control group.
Conclusion The current evidence for intrauterine injection of hCG before fresh ET does not support its use in an assisted reproduction cycle.